Khamashta, Munther
Merrill, Joan T
Werth, Victoria P
Furie, Richard
Kalunian, Kenneth
Illei, Gabor G
Drappa, Jorn
Wang, Liangwei
Greth, Warren
Clinical trials referenced in this document:
Documents that mention this clinical trial
OP0301 Type i ifn gene signature test–high and –low patients with moderate to severe sle disease activity have distinct gene expression signatures of immunologic pathways and cell types
https://doi.org/10.1136/annrheumdis-2017-eular.3719
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
https://doi.org/10.1136/annrheumdis-2015-208562
Documents that mention this clinical trial
OP0301 Type i ifn gene signature test–high and –low patients with moderate to severe sle disease activity have distinct gene expression signatures of immunologic pathways and cell types
https://doi.org/10.1136/annrheumdis-2017-eular.3719
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
https://doi.org/10.1136/annrheumdis-2015-208562
Funding for this research was provided by:
MedImmune